Green Digital Diabetes Waste Project

NCT ID: NCT06071325

Last Updated: 2024-04-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

49 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-09-19

Study Completion Date

2024-04-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine how people with diabetes are disposing of various products and devices and at what rates so that better devices with less waste can be designed in the future.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study aims to compare the amount of environmental waste that is generated during the management of diabetes of participants who are using a CGM and on multiple daily injection (MDI) or using an AID (automated insulin delivery) system. This study is expected to demonstrate which devices create the most waste and where opportunities exist to decrease diabetes device waste. We will collect data to describe both quantitatively (via daily survey) and qualitatively (via photography) the types of waste that are generated during the management of diabetes.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus Diabetes Mellitus, Type 2 Diabetes Mellitus, Type 1

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

AID Group

We anticipate enrolling between 30 and 50 participants who will be recruited to participate in the Automated Insulin Delivery (AID) system study.

No interventions assigned to this group

MDI + CGM Group

We anticipate that between 10 and 30 participants will be enrolled in the study and will be utilizing Multiple Daily Injections (MDI) therapy in conjunction with Continuous Glucose Monitoring (CGM). MDI therapy will be defined as administering three or more injections per day.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Person with diabetes (self-identified), either type 1 or type 2, who has been diagnosed at least 6 months earlier
* Age 18 years and above
* Use of a CGM
* Use of an insulin pump or on MDI
* Access to the Internet and e-mail
* Access to a smartphone with photographic capability
* Able and willing to provide informed consent

* Any condition which, in the opinion of an investigator, would make the subject not qualified to participate in the study.
* Adults unable to consent
* Adults unable to speak English
* Individuals who are not yet adults (infants, children, teenagers)
* Pregnant women
* Prisoners
* Cognitively impaired adults
Minimum Eligible Age

18 Years

Maximum Eligible Age

120 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Diabetes Technology Society

OTHER

Sponsor Role collaborator

Florida State University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jing Wang

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jing Wang, PhD

Role: PRINCIPAL_INVESTIGATOR

Dean & Prof. of FSU College of Nursing

David C Klonoff, MD

Role: PRINCIPAL_INVESTIGATOR

President of Diabetes Technology Society and Clinical Professor of UCSF Medicine

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Diabetes Technology Society

Burlingame, California, United States

Site Status

Florida State University

Tallahassee, Florida, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

STUDY00004453

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

The Diabetes TeleCare Study
NCT00288132 COMPLETED NA
Hypoglycemia Prevention and Awareness Program
NCT06775288 ACTIVE_NOT_RECRUITING NA
Diabetes Clinical Decision Support
NCT05447806 RECRUITING NA